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Abstract: Although blood transfusions are important for patients with anemia, chronic trans-
fusions inevitably lead to iron overload as humans cannot actively remove excess iron. The 
cumulative effects of iron overload lead to signiﬁ  cant morbidity and mortality, if untreated. 
Although the current reference standard iron chelator deferoxamine has been used clinically for 
over four decades, its effectiveness is limited by a demanding therapeutic regimen that leads 
to poor compliance. Deferasirox (Exjade®, ICL670, Novartis Pharma AG, Basel, Switzerland) 
is a once-daily, oral iron chelator approved for the treatment of transfusional iron overload in 
adult and pediatric patients. The efﬁ  cacy and safety of deferasirox have been established in 
a comprehensive clinical development program involving patients with various transfusion-
dependent anemias. Deferasirox has a dose-dependent effect on iron burden, and is as efﬁ  ca-
cious as deferoxamine at comparable therapeutic doses. Deferasirox therapy can be tailored to 
a patient’s needs, as response is related to both dose and iron intake. Since deferasirox has a 
long half-life and is present in the plasma for 24 hours with once-daily dosing, it is unique in 
providing constant chelation coverage with a single dose. The availability of this convenient, 
effective, and well tolerated therapy represents a signiﬁ  cant advance in the management of 
transfusional iron overload.
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Iron chelation therapy
It is well known that red blood cell transfusions are a vital, life-saving treatment for 
many patients with chronic anemias, including β-thalassemia, myelodysplastic syn-
dromes (MDS), and sickle cell disease (SCD). Since every unit of transfused blood 
contains 200–250 mg of iron and the human body has no mechanism to actively 
excrete excess iron, cumulative iron overload is an inevitable consequence of chronic 
transfusion therapy (Porter 2001a).
During normal iron homeostasis, circulating iron is bound to transferrin, a dedi-
cated iron-binding protein with a high afﬁ  nity for ferric (Fe3+) iron. When a state of 
iron overload occurs, the capacity for transferrin to bind iron is exceeded and ‘free’ or 
nontransferrin-bound iron (NTBI) is formed; the presence of NTBI has been shown to 
correlate with the appearance of oxidation products and reduced plasma antioxidant 
capacity (De Luca et al 1999; Cighetti et al 2002). Labile plasma iron (LPI), one form 
of NTBI, is redox-active and can be taken up by liver, cardiac, and endocrine cells 
through uptake mechanisms that are independent of the transferrin receptor (Cabantchik 
et al 2005). It is thought that LPI provides an estimation of the total levels of labile 
iron loaded within cells. Excess iron in parenchymal tissues can cause serious clinical 
sequelae, such as cardiac failure, liver disease, diabetes, and eventual death (Ishizaka 
et al 2002; Cunningham et al 2004). Without treatment, the prognosis for patients with 
iron overload is poor (Brittenham et al 1994).
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As such, the primary aim of iron chelation therapy is to 
bind to and remove iron from the body at a rate that is either 
equal to the rate of transfusional iron input (maintenance 
therapy) or greater than iron input (reduction therapy). 
This suggests that a therapy which allows ﬂ  exible dos-
ing is required. It has been established that iron chelation 
therapy reduces the risk for developing co-morbidities and 
improves patient survival during more than 40 years of clini-
cal experience with the current reference standard chelator 
deferoxamine (DFO) (Desferal®, Novartis Pharma AG, 
Basel, Switzerland) (Brittenham et al 1994; Olivieri et al 
1994; Modell et al 2000). Another aim of chelation therapy 
is to provide constant, 24-hour protection from the harm-
ful effects of toxic iron (ie, NTBI), since gaps in chelation 
therapy result in iron reloading and further tissue damage. 
The direct capture of LPI has been suggested as a way to 
avoid the dangerous accumulation of cellular iron and to 
prevent resultant adverse consequences (Cabantchik et al 
2005). However, 24-hour chelation coverage is not possible 
with ‘standard’ DFO as it is a large molecule with a short 
half-life (20–30 minutes) and plasma levels decline rapidly 
after infusion (Porter et al 1996; Porter 2001b). In one study, 
levels of LPI rebounded as soon as the DFO infusion was 
stopped (Cabantchik et al 2005). DFO administration also 
requires slow parenteral infusion over an 8–12-hour period, 
ﬁ  ve to seven times per week (at a standard dose of 20–60 
mg/kg/day) (Porter 2001b). The demands of this regimen 
have a signiﬁ  cant impact on compliance, meaning that a 
large number of patients do not gain the full beneﬁ  ts of 
therapy and therefore die prematurely (Brittenham et al 
1994; Wonke 2001). One study has demonstrated that the 
probability of survival to at least 25 years of age in poorly 
chelated patients with β-thalassemia major was just one-
third that of patients who were well chelated with DFO 
(Brittenham et al 1994). The number of days a patient was 
receiving chelation was more important than the overall 
dose, indicating that it is essential to maximize the length 
of exposure to chelation therapy.
Deferiprone (Ferriprox®, Apotex, Toronto, ON, Canada), 
a three-times daily oral iron chelator (at a standard dose of 75 
mg/kg/day), is currently available in a number of countries 
outside the USA and Canada for the second-line treatment 
of iron overload in adult patients with thalassemia major for 
whom DFO therapy is contraindicated or inadequate (Hoff-
brand et al 2003; Apotex 2004). Deferiprone has a half-life 
of 3–4 hours and, like DFO, it is therefore unable to provide 
24-hour chelation coverage; LPI levels have been shown 
to rebound in between doses (Cabantchik et al 2005). Use 
of deferiprone is limited to second-line therapy primarily 
due to the occurrence of side effects such as arthropathy, 
neutropenia and, rarely, agranulocytosis (al Refaie et al 
1995; EMEA 2005). In addition, data on its use in pediatric 
patients are limited.
Development of deferasirox
Deferasirox (Exjade®, ICL670) was developed in response to 
the clear need for a convenient, effective and well-tolerated 
iron chelating agent. The development process began in 1993, 
when Novartis (Basel, Switzerland) produced over 700 iron 
chelating compounds with high afﬁ  nity and selectivity for 
iron. Using a computational chemistry-based model, the 
bis-hydroxyphenyl-triazole class showed the most promise, 
as it combined the relevant iron chelating attributes with the 
potential to synthesize various derivatives. Approximately 
40 compounds with this structure were synthesized. Just one 
molecule, known as ‘ICL670’ or deferasirox, passed this test 
and subsequently entered a rigorous clinical development 
program in 1998.
Deferasirox: properties 
and administration
Deferasirox is a tridentate iron chelator, meaning that two 
molecules are required to form a stable complex with each 
iron (Fe3+) atom. The active molecule (ICL670) is highly 
lipophilic and 99% protein-bound. The key chelation proper-
ties of deferasirox are:
•  High and speciﬁ  c afﬁ  nity for Fe3+ (approximately 
14 and 21 times greater than its afﬁ  nity for copper 
[Cu2+] and zinc [Zn2+], respectively [Steinhauser et al 
2004])
•  Oral bioavailability
•  Highly efﬁ  cient and efﬁ  cacious
•  Effective at multiple doses; allowing ﬂ  exible regimens
•  Long half-life (8–16 hours); allowing once-daily 
dosing
•  Generally well tolerated
The long half-life means that deferasirox can be taken once 
a day (standard dose of 20–30 mg/kg/day). Tablets should 
be completely dispersed by stirring in water, orange juice, 
or apple juice until a ﬁ  ne suspension is obtained; this oral 
formulation means that deferasirox is easy-to-use for pedi-
atric patients. Any residue should be resuspended in a small 
volume of liquid and swallowed to avoid introducing vari-
ability in bioavailability. For the same reason, deferasirox 
should be taken on an empty stomach at least 30 minutes 
before food (Exjade PI 2005).Therapeutics and Clinical Risk Management 2007:3(2) 293
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Preclinical studies
In vivo animal pharmacology
As demonstrated in various animal models, deferasirox is 
rapidly absorbed, can efﬁ  ciently and selectively mobilize iron 
from various tissues such as hepatocytes and cardiomyocytes, 
and can promote iron excretion (Nick et al 2002, 2003). As 
the deferasirox-iron complex is relatively inert, it is excreted 
in the feces rather than being redistributed (Nick et al 2002). 
In an iron overloaded rat model, the efﬁ  ciency of deferasirox 
(ie, the ratio of iron excreted to the theoretical maximum of 
iron that could be bound by the dose given) was high—18% 
at doses of 50 mg/kg and 100 mg/kg—compared with 
both subcutaneous DFO (3%–4%) and deferiprone (~2%) 
(Nick et al 2003).
Safety/toxicology studies
Iron is a physiologically important element with a num-
ber of very important roles (eg, in erythropoiesis, oxygen 
transport, and DNA synthesis), therefore the potential for 
deferasirox to affect normal iron absorption was evaluated. 
A rat model demonstrated that deferasirox does not affect 
normal homeostatic uptake of dietary iron. This means that 
the deferasirox-iron complex does not permeate the muco-
sal cell layer. Further evidence of this was obtained using 
the Caco2 cell monolayer model (Nick et al 2002, 2003). 
Deferasirox was generally well tolerated across a wide range 
of toxicology studies, and no toxicities prohibitive for use 
in humans were identiﬁ  ed. The kidney (tubular region) was 
the primary organ affected by iron overload in both rats and 
marmosets, with the severity of effects being dependent on 
the iron loading status of the animals.
Effect on iron burden in animals
The ability of deferasirox to reduce iron burden has been 
demonstrated in a number of animal models, producing 
significant reductions in liver iron concentration (LIC) 
and demonstrating greater efficacy than DFO and sig-
nificantly greater efficacy than deferiprone (Nick et al 
2002, 2003). As cardiac failure is a primary cause of 
morbidity and mortality in patients with transfusional 
iron overload, it is important that an iron chelator is able 
to remove iron from the heart. A study in rat heart cell 
cultures initially demonstrated the ability of deferasirox 
to remove iron directly from iron-loaded myocardial cells 
(Hershko et al 2001). More recently, a fluorescence study 
in living cells clearly demonstrated that deferasirox can 
access and chelate intracellular iron in cardiomyocytes 
(Glickstein et al 2005). The relative efficacy of defera-
sirox, deferiprone, and DFO has been evaluated in an 
iron-loaded gerbil model (Wood et al 2005). Deferasirox 
and deferiprone were equally effective, decreasing cardiac 
iron levels by 20.5% and 18.6%, respectively, although 
deferasirox was significantly more effective for reduc-
ing liver iron levels. This observation suggests that de-
ferasirox may be effective in multiple areas of the body. 
Both drugs were significantly more effective than DFO, 
which did not reduce iron levels in this study, although 
this was most likely due to the mode of administration 
used. Preliminary data show that deferasirox is also 
effective for removing excess cardiac iron, as measured 
by an improvement in myocardial T2*, over 1 year of 
treatment in human thalassemia patients (Eleftheriou 
et al 2006). To date, this improvement in T2* has been 
maintained over 2 years of deferasirox treatment. As such, 
DFO and deferiprone appear effective for removing car-
diac iron (Borgna-Pignatti et al 2006; Pennell et al 2006), 
as does deferasirox (Eleftheriou et al 2006).
Clinical evaluation
Deferasirox is currently approved in many countries, inclu-
ding the USA, Switzerland, and Europe, for the treatment 
of chronic transfusional iron overload in adult and pediatric 
patients (Exjade PI 2005). These approvals were obtained 
based on the results from a comprehensive series of studies, 
the largest ever undertaken for an iron chelating agent, that 
enrolled over 1000 patients with a wide range of transfu-
sion-dependent anemias (Figure 1). As many patients require 
transfusion therapy from childhood, a large number of pedi-
atric patients were enrolled to investigate efﬁ  cacy and safety 
of deferasirox in this important population.
Pharmacokinetic proﬁ  le of deferasirox
In Study 101 it was shown that the serum concentration of 
deferasirox is proportional to the dose administered (Figure 2) 
(Galanello et al 2003). This study also demonstrated that 
unbound deferasirox had a mean half-life of 11–19 hours 
depending on dose, which supports the once-daily dosing 
regimen used throughout the clinical trial program. Defera-
sirox plasma levels were also shown to be maintained within 
the therapeutic range over a 24-hour period (20 mg/kg/day: 
peak levels ~60–100 µmol/L, trough levels ~15–20 µmol/L), 
providing constant gap-free chelation coverage with a single 
daily dose (Nisbet-Brown et al 2003).Therapeutics and Clinical Risk Management 2007:3(2) 294
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The pharmacokinetic (PK) proﬁ  le of deferasirox has 
been evaluated in patients with different ethnic back-
grounds, where no signiﬁ  cant differences were observed, 
and also in pediatric patients with β-thalassemia major after 
administration of single and multiple oral doses (Study 106). 
The results in pediatric patients showed no differences in maxi-
mum concentration, area under the curve, and half-life between 
children (aged <12 years) and adolescents (aged ≥12 years), al-
though exposure to deferasirox was approximately 20%–30% 
lower than that previously observed in adult β-thalassemia 
patients (Galanello et al 2006). These PK characteristics 
demonstrate that deferasirox is suitable for once-daily oral 
administration in pediatric patients. It is interesting to note 
that patients aged <6 years had signiﬁ  cantly lower exposure 
to deferasirox than other pediatric patients, which may pro-
vide an additional margin for safety and tolerability.
Effect on iron burden in humans
The proof-of-concept for deferasirox in humans was achieved 
by a dose escalation study in patients with β-thalassemia and 
transfusional iron overload that demonstrated good efﬁ  cacy 
and a chelation efﬁ  ciency of up to 20.5% (Study 104) (Nis-
bet-Brown et al 2003). This study identiﬁ  ed an effective 
dose between 20–30 mg/kg/day, similar to what had been 
previously observed in marmosets. Data from a subsequent 
1-year, Phase II comparative study in transfusion-dependent 
β-thalassemia patients (Study 105) provided the ﬁ  rst evidence 
that deferasirox efﬁ  cacy was comparable with DFO (Piga 
et al 2006). In this study, a single daily dose of deferasirox 
20 mg/kg/day was as effective as DFO 40 mg/kg/day for 
removing iron. 
Pivotal data have been recently published from a large-
scale, randomized Phase III trial comparing deferasirox 
(n = 296) with subcutaneous DFO (n = 290) in 
regularly transfused adult and pediatric patients 
with transfusion-dependent β-thalassemia (Study 
107) (Cappellini et al 2006). Dose was assigned ac-
cording to baseline LIC; those with baseline LIC 
<7 mg Fe/g dry weight (dw) received deferasirox 5 or 
10 mg/kg/day or DFO <25–<35 mg/kg, and those with 
baseline LIC ≥7 mg Fe/g dw received deferasirox 20 
or 30 mg/kg/day or DFO 35–≥50 mg/kg. Baseline LIC 
values were very high in this population, despite the fact 
that most patients were receiving DFO therapy prior to 
study entry and were judged to be suitable for continued 
treatment, highlighting the significant unmet medical 
need in this population. As the study design allowed 
patients receiving DFO at study entry to continue on 
their current dose even if it was higher than would have 
been assigned by the protocol, patients with LIC values 
<7 mg Fe/g dw received lower doses of deferasirox rela-
tive to DFO as compared with patients with LIC ≥7 mg 
Figure 1 Deferasirox clinical trial program. 
Abbreviations: DFO, deferoxamine; LIC, liver iron concentration; SCD, sickle cell disease.Therapeutics and Clinical Risk Management 2007:3(2) 295
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Figure 2 Mean plasma concentrations (+ SD) of deferasirox are proportional to dose. Copyright © 2003. Reprinted with permission from Galanello R, Piga A,  Alberti D, 
et al. 2003. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-
thalassemia. J Clin Pharmacol, 43:565–72.
Table 1 Protocol-assigned and actual doses used during Study 107
   Deferasirox,  mg/kg/day
Protocol assigned dose  5  10  20  30
Actual mean dose ± SD  6.2 ± 1.6  10.2 ± 1.2  19.4 ± 1.7  28.2 ± 3.5
   DFO,  mg/kg/day
Protocol assigned dose  <25  25–<35  35–<50  ≥50
Actual mean dose ± SD  33.9 ± 9.9  36.7 ± 9.2  42.4 ± 6.6  51.6 ± 5.8
Ratio of actual deferasirox: DFO doses  1:5.5  1:3.6  1:2.2  1:1.8
Abbreviations: DFO, deferoxamine; SD, standard deviation.
Fe/g dw. The net result was that doses were not compa-
rable in the lower deferasirox dose ranges (Table 1). 
Due to this disproportionate dosing, the primary end-
point (a nonparametric ‘success’ or ‘failure’ endpoint that 
was prospectively deﬁ  ned for each dose group) was not met 
in the overall population. However, there was still a clear 
demonstration of dose-dependent iron excretion (Figure 3). 
Furthermore, in patients with baseline LIC values ≥7 mg Fe/g 
dw (69%) where a deferasirox versus DFO dose relationship 
of 1:2 was maintained; similar changes in iron burden were 
achieved in both treatment groups. It was clear that iron bal-
ance was achieved at the recommended deferasirox starting 
dose of 20 mg/kg/day, and a signiﬁ  cant reduction in iron 
burden was observed at 30 mg/kg/day (Table 2) (Cappellini 
et al 2006). Overall, changes in LIC, serum ferritin and body 
iron balance were consistent during the study and correlated 
well with one another.
Pooled data from across the deferasirox clinical trial pro-
gram have demonstrated that the response to deferasirox is not 
only dependent on dose, but also on the rate of transfusional iron 
intake while on study (Cohen et al 2005; Greenberg et al 2005). 
Although the impact of transfusion rate was underestimated in 
these studies, it did enable a comparison of various transfusion 
rates at each dose. As shown in Figure 4, this led to the deﬁ  nition 
of some general guidance on deferasirox dosing:
•  10 mg/kg/day maintains iron balance in patients with low 
transfusional requirements (<2 units of blood/month)
•  20 mg/kg/day maintains or reduces iron balance in 
patients with low and intermediate requirements (2–4 
units of blood/month)Therapeutics and Clinical Risk Management 2007:3(2) 296
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•  30 mg/kg/day decreases iron balance in most patients, 
irrespective of transfusional requirements
Deferasirox dosing can therefore be tailored to meet a 
patient’s need based on transfusional requirements, sever-
ity of iron overload, and treatment goal (ie, maintenance or 
reduction of body iron levels). As deferasirox has high and 
stable efﬁ  ciency across doses (approximately 30% [Porter 
et al 2005]), 5 mg/kg/day is able to effectively remove iron 
but is insufﬁ  cient to maintain or reduce iron balance in 
regularly transfused patients.
Efﬁ  cacy in a range 
of transfusion-dependent anemias
As complications of iron overload have been best studied 
in β-thalassemia, this population of patients was the main 
focus of the deferasirox clinical trial program. However, a 
number of regularly transfused patients with different chronic 
anemias have also been enrolled, including MDS, SCD, and 
Diamond-Blackfan anemia (DBA). Given that the patho-
genesis of chronic iron overload may vary across different 
transfusion-dependent anemias, it was important to investigate 
whether efﬁ  cacy results were comparable, so that response to 
therapy could be monitored and treatment tailored to meet the 
needs of each individual patient. Preliminary data from patients 
with MDS and DBA (Study 108), as well as SCD (Study 109), 
demonstrate signiﬁ  cant, dose-dependent effects on LIC and 
serum ferritin over the 1-year treatment period, which were 
similar to results seen in thalassemia patients (Gattermann 
et al 2005; Tchernia et al 2005; Vichinsky, Fischer, Fung, 
et al 2005). The National Comprehensive Cancer Network 
(NCCN) has recently published updated clinical practice 
guidelines for MDS, recognizing the importance of constant 
chelation coverage and introducing deferasirox into its treat-
ment recommendations (Greenberg et al 2006). Importantly, 
deferasirox has also been shown to be effective in patients 
who were previously inadequately chelated with DFO (due 
to poor tolerance or compliance, or contraindications), sug-
gesting that deferasirox is effective in both chelation-naïve 
and chelation-experienced patients.
Constant chelation coverage and impact 
on toxic iron levels
As discussed previously, deferasirox has a long half-life and 
plasma levels are maintained within the therapeutic range 
over the entire 24-hour period. This is important as it means 
that deferasirox is able to provide 24-hour chelation coverage 
with a single oral dose. In contrast, chelation coverage with 
other available iron chelators is limited to periods of drug 
exposure only. For example, plasma levels of DFO rapidly 
fall below detectable levels thus limiting chelation coverage 
Table 2 Change in serum ferritin and iron excretion/intake ratio after 1-year of deferasirox treatment
    Median deferasirox dose, mg/kg/day
 5  10  20  30
Change in serum ferritin*, µg/L  1189 ± 700  833 ± 817  –36 ± 817  –926 ± 1416
Ratio iron excretion/intake*  0.58 ± 0.33  0.67 ± 0.37  1.02 ± 0.40  1.67 ± 0.72
Note: *Mean ± Standard deviation.
Figure 3 Dose-dependent change in LIC with deferasirox treatment [ Deferasirox;  DFO]. Copyright © 2006. Reprinted with permission from Cappellini MD, Cohen A, 
Piga A, et al. 2006.  A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood, 107:3455–62. Therapeutics and Clinical Risk Management 2007:3(2) 297
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to the duration of the infusion only (Porter et al 1996). As 
such, levels of toxic LPI are at times poorly controlled with 
DFO (Cabantchik et al 2005). This is also true for deferi-
prone monotherapy, with toxic LPI rebounding signiﬁ  cantly 
between doses (Cabantchik et al 2005). Levels are more fully 
controlled with sequential combination therapy, although this 
regimen must be prescribed 7 days/week in order to provide 
constant chelation coverage. As deferasirox is convenient and 
taken once daily, it is continually present in the circulation 
and provides chelation coverage 24 hours/day, 7 days/week, 
thereby providing greater control of LPI. This has been 
investigated as part of a deferasirox clinical trial program. 
Preliminary data in patients with β-thalassemia demonstrate 
that daily trough levels of deferasirox are sufﬁ  cient to main-
tain suppression of LPI levels, suggesting that deferasirox 
is able to control LPI for 24 hours with a single dose (Daar 
et al 2006). After 4 weeks of treatment with deferasirox 
(20 mg/kg/day), peak LPI levels observed just before de-
ferasirox dosing were signiﬁ  cantly decreased compared 
with baseline and were close to normal levels, indicating a 
sustained reduction in LPI.
Safety and tolerability proﬁ  le
Deferasirox has been shown to be generally well tolerated in 
adults and children with different chronic anemias. Of 652 
patients who received deferasirox in the core clinical trials 
(Studies 106, 107, 108, and 109), none experienced drug-
related neutropenia or agranulocytosis, which were serious 
adverse events (AEs) observed during treatment with other 
chelators (Piga et al 2004; Gattermann et al 2005; Cappel-
lini et al 2006). Sporadic cases were observed, but were 
considered by the investigators to be due to the underlying 
condition rather than deferasirox therapy.
The most frequent AEs reported during chronic 
treatment with deferasirox include transient mild-
to-moderate gastrointestinal disturbances (~26% of patients) 
and transient mild-to-moderate skin rash (~7% of patients). 
These events rarely required drug discontinuation and many 
resolved spontaneously. Mild, non-progressive increases in 
serum creatinine (generally within upper limit of normal 
[ULN]) were observed in 34% of patients, although these are 
not currently thought to be clinically signiﬁ  cant as they were 
temporary and reversible. There were no cases of moderate 
to severe renal insufﬁ  ciency or renal failure and no patients 
permanently discontinued therapy due to creatinine rises 
in the core, 1-year studies. Increases above the ULN were 
observed in 2% of patients with β-thalassemia major and 
16% with other anemias, including geriatric patients whose 
baseline creatinine levels were close to the ULN. Exten-
sion studies are ongoing to collect long-term data on these 
increases in serum creatinine. Two patients (2/703; 0.3%) 
experienced elevated alanine aminotransferase levels (>5 × 
ULN) for which an association with deferasirox treatment 
could not be ruled out. 
Deferasirox is also generally well tolerated in children 
as young as 2 years of age, with a safety proﬁ  le similar to 
Figure 4 Deferasirox demonstrates dose- and transfusion-related changes in LIC (pooled data).
Abbreviations: LIC, liver iron concentration.Therapeutics and Clinical Risk Management 2007:3(2) 298
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that observed in adults (Piga et al 2004). To date, sexual 
and physical development have proceeded normally during 
treatment with deferasirox (Forni et al 2005).
Patients have been followed in the extension phases of the 
clinical trials for over 2 years; AE data from up to 5 years’ 
deferasirox treatment will eventually be collected.
Patients prefer deferasirox to DFO
It is generally recognized that ‘real world’ treatment compli-
ance cannot be effectively assessed in the clinical trial setting. 
As such, two deferasirox studies in patients with β-thalasse-
mia and SCD evaluated actual patient feedback in the form of 
patient-reported outcomes (Cappellini et al 2005; Vichinsky, 
Fischer, Pakbaz, et al 2005). Most patients who had previ-
ously received DFO were more satisﬁ  ed with deferasirox 
therapy than DFO (85.15% vs 38.7% in β-thalassemia and 
84.3% vs 23.7% in SCD, respectively), and found it to be 
more convenient than DFO (92.7% vs 11.3% in β-thalassemia 
and 79.5% vs 18.4% in SCD, respectively). These ﬁ  ndings 
are supported by the impact of chelation therapy on normal 
daily activities, with less time being lost each month due to 
therapy with deferasirox than DFO (1.5–2.8 vs 11.1–11.7 
hours in β-thalassemia and 2–3 versus 6–28 hours in SCD, 
respectively). Superior satisfaction with, and convenience 
of, deferasirox therapy versus DFO may translate into actual 
patient compliance and increase the effectiveness of chelation 
therapy, optimizing the outcome of iron-overloaded transfu-
sion-dependent patients.
Conclusions
Iron overload, a cumulative toxicity, is an inevitable con-
sequence of chronic transfusion therapy. With the value of 
transfusion therapy in various chronic anemias becoming 
more widely appreciated, its use is likely to increase in the 
future. Although iron levels can be controlled with DFO 
therapy, poor compliance with the demanding therapeutic 
regimen in many patients and a lack of constant chelation 
coverage signiﬁ  cantly limits its effectiveness, leaving many 
patients exposed to the toxic effects of iron overload. Con-
venient, effective and well-tolerated chelation therapy with 
oral deferasirox is likely to be a signiﬁ  cant development in 
the treatment of transfusional iron overload due to its abil-
ity to provide constant chelation coverage and the potential 
to improve compliance. In addition, this novel agent may 
allow treatment to be initiated at an earlier stage in the disease 
course due to its excellent efﬁ  cacy and tolerability proﬁ  le 
combined with a convenient administration regimen. 
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